



09-22-03

**PATENT APPLICATION**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s): Kinstler, et al.

Serial No.: 10/622,998

Group Art Unit No.:

Filed: July 18, 2003

Examiner:

For: Protein Conjugates with a Water-Soluble  
Biocompatible, Biodegradable Polymer

Docket No.: A-822

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

As a means of complying with the duty of disclosure under 37 CFR 1.97 and 1.98, applicant(s) submit(s) a "List of References Cited by Applicant" on a modified PTO-1449 form and provide(s) a copy of each of the listed references for consideration by the Examiner, with the exception of submitting a copy of each cited U.S. patent and each U.S. patent application publication filed after June 30, 2003 which is hereby waived under the requirement of 37 CFR 1.98 (a)(2)(i).

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, or before the mailing of a first Office action after the filing of a request for continued examination under section 1.114, whichever event occurs last. 37 CFR 1.97(b).

Applicant(s) request(s) consideration of this information and passage of the application to issue.

The Commissioner is hereby authorized to charge any filing fees, which may be required or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen Inc.

Please send all future correspondence to:

US Patent Operations/ RNM  
Dept. 4300, M/S 27-4-A  
AMGEN INC.  
One Amgen Center Drive  
Thousand Oaks, California 91320-1799

Respectfully submitted,

Randolph N. Mohr  
Attorney/Agent for Applicant(s)  
Registration No.: 45,590  
Phone: (805) 447-8949  
Date: September 18, 2003

**EXPRESS MAIL CERTIFICATE**

"Express Mail" mail labeling number: EV 351339290 US

Date of Deposit: September 18, 2003

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Sherry St. Andrew  
Printed Name

Signature



**PATENT APPLICATION**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s): Kinstler, et al.

Serial No.: 10/622,998

Group Art Unit No.:

Filed: July 18, 2003

Examiner:

For: Protein Conjugates with a Water-Soluble  
Biocompatible, Biodegradable Polymer

Docket No.: A-822

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

As a means of complying with the duty of disclosure under 37 CFR 1.97 and 1.98, applicant(s) submit(s) a "List of References Cited by Applicant" on a modified PTO-1449 form and provide(s) a copy of each of the listed references for consideration by the Examiner, with the exception of submitting a copy of each cited U.S. patent and each U.S. patent application publication filed after June 30, 2003 which is hereby waived under the requirement of 37 CFR 1.98 (a)(2)(i).

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, or before the mailing of a first Office action after the filing of a request for continued examination under section 1.114, whichever event occurs last. 37 CFR 1.97(b).

Applicant(s) request(s) consideration of this information and passage of the application to issue.

The Commissioner is hereby authorized to charge any filing fees, which may be required or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen Inc.

Please send all future correspondence to:

US Patent Operations/ RNM  
Dept. 4300, M/S 27-4-A  
AMGEN INC.  
One Amgen Center Drive  
Thousand Oaks, California 91320-1799

Respectfully submitted,

Randolph N. Mohr  
Attorney/Agent for Applicant(s)  
Registration No.: 45,590  
Phone: (805) 447-8949  
Date: September 18, 2003

**EXPRESS MAIL CERTIFICATE**


"Express Mail" mail labeling number: EV 351339290 US

Date of Deposit: September 18, 2003

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Sherry St. Andrew  
Printed Name

  
Signature



Modified Form PTO-1449	Atty. Docket No. A-822	Serial No. 10/622.998
<b>LIST OF REFERENCES CITED BY APPLICANT</b>  (Use several sheets if necessary)	Applicant Kinstler, et al.	
	Filing Date July 18, 2003	Group

### U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
	A1	5,075,222	Dec 24, 1991	Hannum, et al			
	A2	5,811,510	Sept 22, 1998	Papisov			
	A3	5,824,784	Oct 20, 1998	Kinstler, et al			
	A4	5,863,990	Jan 26, 1999	Papisov			
	A5	5,958,398	Sept 28, 1999	Papisov			
	A6						
	A7						
	A8						
	A9						

### FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
							YES	NO
	B1	WO 96/05309	22 Feb 1996	PCT				
	B2	WO 96/40912	19 Dec 1996	PCT				
	B3							
	B4							
	B5							

### OTHER DOCUMENTS (Including Publisher, Author, Title, Date, Pertinent Pages, Etc.)

C1	Conover, et al., <b>Physiological Effect of Polyethylene Glycol Conjugation on Stroma-Free Bovine Hemoglobin in the Conscious Dog After Partial Exchange Transfusion</b> , Artificial Organs, 21, (5): 369-378 (1997)
C2	Bendele, et al., <b>Short Communication: Renal Tubular Vacuolation in Animals Treated with Polyethylene-Glycol-Conjugated Proteins</b> , Toxicological Sciences, 42: 152-157 (1997)
C3	
C4	
C5	
C6	

EXAMINER:	Date Considered:
-----------	------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.